Ligand Enters OmniAb® License Agreement with TeneoBio, Inc.
Ligand Initiates Phase 2 Trial with LGD-6972 in Type 2 Diabetes
Ligand Partner Retrophin Announces Positive Top-Line Results from Phase 2 DUET Study of Sparsentan in Patients with Focal Segmental Glomerulosclerosis
Ligand to Participate in Two Upcoming Investor Conferences
Results from Phase 1 Trials with Ligand’s LGD-6972 in Type 2 Diabetes Mellitus Published in Diabetes, Obesity and Metabolism
Ligand Reports Second Quarter 2016 Financial Results
Ligand Announces Multi-Program LTP Technology Licensing Agreement with Nucorion Pharmaceuticals
Ligand to Report Second Quarter Results on August 4th
Ligand Enters into OmniAb® Platform License Agreement with Gilead Sciences
Ligand Receives $4 Million from Expansion of Two OmniAb® License Agreements
Ligand Reports First Quarter 2016 Financial Results
Ligand Acquires Portfolio of Synthetic Royalty and Milestone Rights from CorMatrix® Cardiovascular for $17.5 Million
Ligand Announces First Quarter 2016 Earnings Reporting Date and Participation in Four Upcoming Investor Conferences
Revolade® Approved in EU as First in Class Therapy for Children Aged 1 Year and Above with Chronic ITP
